Lille, 6th September 2016
OCR, the company revolutionising the selection of effective drug candidates for cancer, raises €1.25m from Newfund, NFA and the management team in order to accelerate its growth.
« Because we were vets before becoming researchers, our first responsibility is the quality of life and the quality of care for the pets we look after, working closely with their own veterinary clinics, in their fight against cancer. »
CLINICAL
RESEARCH
OCR is specialized in the conception
and management of clinical trials of pets
with naturally occurring pathologies for
efficacy assessment of drug candidates &
medical devices for Human and Animal Health.
For further information, please contact us.
contact@oncovet-clinical-research.com
+33 (0)3 20 56 82 93
Parc Eurasanté, Lille Métropole
80 Rue du Docteur Yersin, 59120 Loos
FRANCE
+33 (0)3.20.56.82.93
OCR, the company revolutionising the selection of effective drug candidates for cancer, raises €1.25m from Newfund, NFA and the management team in order to accelerate its growth.
OCR emerges as a leading vet CRO in Europe after signing a succession of major contracts
OCR and Pierre Fabre’s Phase I Clinical Pharmacology Study published in prestigious Clinical Cancer Research journal
OCR represented at 106th AACR Annual Meeting by Dr. Grégoire Prevost
OCR and Ecrins Therapeutics initiate €1.9m “Dog to Man” pioneering translational research programme to advance human and vet oncology treatment
OCR and PRISM announce ground-breaking research collaboration to advance real-time diagnosis using mass spectrometry
OCR strengthens veterinary and R&D expertise to respond to the needs of the pharmaceutical industry
Stay connected to OCR,
subscribe to our Newsletter !